Rituximab for desensitization during HLA-mismatched stem cell transplantation in patients with a positive donor-specific anti-HLA antibody
To define the efficacy of a single dose of 375 mg/m 2 rituximab for DSA-positive patients with 2000 ≤ MFI
Gespeichert in:
| Veröffentlicht in: | Bone marrow transplantation (Basingstoke) 2020-07, Vol.55 (7), p.1326-1336 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1336 |
|---|---|
| container_issue | 7 |
| container_start_page | 1326 |
| container_title | Bone marrow transplantation (Basingstoke) |
| container_volume | 55 |
| creator | Chang, Ying-Jun Xu, Lan-Ping Wang, Yu Zhang, Xiao-Hui Chen, Huan Chen, Yu-Hong Wang, Feng-Rong Han, Wei Sun, Yu-Qian Yan, Chen-Hua Tang, Fei-Fei Huo, Ming-Rui Zhao, Xiang-Yu Mo, Xiao-Dong Liu, Kai-Yan Huang, Xiao-Jun |
| description | To define the efficacy of a single dose of 375 mg/m
2
rituximab for DSA-positive patients with 2000 ≤ MFI |
| doi_str_mv | 10.1038/s41409-020-0928-z |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_2400532049</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A628316939</galeid><sourcerecordid>A628316939</sourcerecordid><originalsourceid>FETCH-LOGICAL-c498t-99fe91d9891db867ae614d7b3f49db7d2035517167d3119eb799b2429ce333093</originalsourceid><addsrcrecordid>eNp9kt1qFTEUhQdR7LH6AN5IQCjepOZvfnJ5KNUKBwTR65CZ7OlJmUnGJFPteQSf2oxTrRWVQBLCt9bOTlZRPKfklBLevI6CCiIxYQQTyRp8eFBsqKgrXPKqfFhsCKsazHklj4onMV4RQoUg5ePiiDPelFzQTfHtg03zVzvqFvU-IAMRXLTJHnSy3iEzB-su0cVui0cbR526PRgUE4yog2FAKWgXp0G7tPLWoSnvwKWIvti0RxpNfvG7BmS88wHHCTrb2w5ljcXZ-Mem9ebmafGo10OEZ7frcfHpzfnHswu8e__23dl2hzshm4Sl7EFSI5s8tU1Va6ioMHXLeyFNWxtGeFnSmla14ZRKaGspWyaY7IBzTiQ_Ll6tvlPwn2eISeXWlm60Az9HxQQhJWdELOjLP9ArPweXb5epuiSC5kr_p6jMTg1t7qhLPYCyrvf58bqltNpWrOG0knypePoXKg8Do-28g97m83uCk98Ee9BD2kc_zMt3xPsgXcEu-BgD9GoK-d_DjaJELXFSa5xUjpNa4qQOWfPitrO5HcH8UvzMTwbYCsRpCQqEu9b_7fodBi7Trw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2419204818</pqid></control><display><type>article</type><title>Rituximab for desensitization during HLA-mismatched stem cell transplantation in patients with a positive donor-specific anti-HLA antibody</title><source>Springer Nature - Complete Springer Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Chang, Ying-Jun ; Xu, Lan-Ping ; Wang, Yu ; Zhang, Xiao-Hui ; Chen, Huan ; Chen, Yu-Hong ; Wang, Feng-Rong ; Han, Wei ; Sun, Yu-Qian ; Yan, Chen-Hua ; Tang, Fei-Fei ; Huo, Ming-Rui ; Zhao, Xiang-Yu ; Mo, Xiao-Dong ; Liu, Kai-Yan ; Huang, Xiao-Jun</creator><creatorcontrib>Chang, Ying-Jun ; Xu, Lan-Ping ; Wang, Yu ; Zhang, Xiao-Hui ; Chen, Huan ; Chen, Yu-Hong ; Wang, Feng-Rong ; Han, Wei ; Sun, Yu-Qian ; Yan, Chen-Hua ; Tang, Fei-Fei ; Huo, Ming-Rui ; Zhao, Xiang-Yu ; Mo, Xiao-Dong ; Liu, Kai-Yan ; Huang, Xiao-Jun</creatorcontrib><description>To define the efficacy of a single dose of 375 mg/m
2
rituximab for DSA-positive patients with 2000 ≤ MFI < 10,000, we enrolled a prospective clinical cohort including patients with positive DSA treated with rituximab (
n
= 55, cohort A), a matched-pair cohort including cases with negative DSA (
n
= 110, cohort B) and a historical cohort including subjects with 2000 ≤ MFI < 10,000 without receiving any treatment for DSA (
n
= 22, cohort C). The incidences of primary poor graft function (PGF) in cohort A and cohort B were 5% and 1% (
P
= 0.076), respectively, both of which were lower than that in cohort C (27%,
P
< 0.001, for all). Rituximab was associated with a reduced incidence of primary PGF (HR 0.200,
P
= 0.023). The 3-year nonrelapse mortality of patients in cohort A and cohort B were 23% and 24%, respectively, both of which were lower than that in the cohort C (37%), although no statistical significance was observed. These results led to a low 3-year overall survival in patients in the cohort C (58%) compared with those in the cohort A (71%) and the cohort B (73%). We suggest that a single dose of rituximab could be effectively used to prevent the onset of primary PGF. The prospective cohort of this study is registered at
http://www.chictr.org.cn/ChiCTR-OPC-15006672
.</description><identifier>ISSN: 0268-3369</identifier><identifier>EISSN: 1476-5365</identifier><identifier>DOI: 10.1038/s41409-020-0928-z</identifier><identifier>PMID: 32385341</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>631/250/1854/2812 ; 631/250/1904 ; Antibodies ; Antithymocyte globulin ; Bone marrow ; Cell Biology ; Desensitization ; Hematology ; Histocompatibility antigen HLA ; Immunotherapy ; Internal Medicine ; Medicine ; Medicine & Public Health ; Monoclonal antibodies ; Patients ; Public Health ; Rituximab ; Stem cell research ; Stem cell transplantation ; Stem Cells ; Transplantation</subject><ispartof>Bone marrow transplantation (Basingstoke), 2020-07, Vol.55 (7), p.1326-1336</ispartof><rights>The Author(s), under exclusive licence to Springer Nature Limited 2020</rights><rights>COPYRIGHT 2020 Nature Publishing Group</rights><rights>The Author(s), under exclusive licence to Springer Nature Limited 2020.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c498t-99fe91d9891db867ae614d7b3f49db7d2035517167d3119eb799b2429ce333093</citedby><cites>FETCH-LOGICAL-c498t-99fe91d9891db867ae614d7b3f49db7d2035517167d3119eb799b2429ce333093</cites><orcidid>0000-0002-2145-6643</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/s41409-020-0928-z$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/s41409-020-0928-z$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32385341$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chang, Ying-Jun</creatorcontrib><creatorcontrib>Xu, Lan-Ping</creatorcontrib><creatorcontrib>Wang, Yu</creatorcontrib><creatorcontrib>Zhang, Xiao-Hui</creatorcontrib><creatorcontrib>Chen, Huan</creatorcontrib><creatorcontrib>Chen, Yu-Hong</creatorcontrib><creatorcontrib>Wang, Feng-Rong</creatorcontrib><creatorcontrib>Han, Wei</creatorcontrib><creatorcontrib>Sun, Yu-Qian</creatorcontrib><creatorcontrib>Yan, Chen-Hua</creatorcontrib><creatorcontrib>Tang, Fei-Fei</creatorcontrib><creatorcontrib>Huo, Ming-Rui</creatorcontrib><creatorcontrib>Zhao, Xiang-Yu</creatorcontrib><creatorcontrib>Mo, Xiao-Dong</creatorcontrib><creatorcontrib>Liu, Kai-Yan</creatorcontrib><creatorcontrib>Huang, Xiao-Jun</creatorcontrib><title>Rituximab for desensitization during HLA-mismatched stem cell transplantation in patients with a positive donor-specific anti-HLA antibody</title><title>Bone marrow transplantation (Basingstoke)</title><addtitle>Bone Marrow Transplant</addtitle><addtitle>Bone Marrow Transplant</addtitle><description>To define the efficacy of a single dose of 375 mg/m
2
rituximab for DSA-positive patients with 2000 ≤ MFI < 10,000, we enrolled a prospective clinical cohort including patients with positive DSA treated with rituximab (
n
= 55, cohort A), a matched-pair cohort including cases with negative DSA (
n
= 110, cohort B) and a historical cohort including subjects with 2000 ≤ MFI < 10,000 without receiving any treatment for DSA (
n
= 22, cohort C). The incidences of primary poor graft function (PGF) in cohort A and cohort B were 5% and 1% (
P
= 0.076), respectively, both of which were lower than that in cohort C (27%,
P
< 0.001, for all). Rituximab was associated with a reduced incidence of primary PGF (HR 0.200,
P
= 0.023). The 3-year nonrelapse mortality of patients in cohort A and cohort B were 23% and 24%, respectively, both of which were lower than that in the cohort C (37%), although no statistical significance was observed. These results led to a low 3-year overall survival in patients in the cohort C (58%) compared with those in the cohort A (71%) and the cohort B (73%). We suggest that a single dose of rituximab could be effectively used to prevent the onset of primary PGF. The prospective cohort of this study is registered at
http://www.chictr.org.cn/ChiCTR-OPC-15006672
.</description><subject>631/250/1854/2812</subject><subject>631/250/1904</subject><subject>Antibodies</subject><subject>Antithymocyte globulin</subject><subject>Bone marrow</subject><subject>Cell Biology</subject><subject>Desensitization</subject><subject>Hematology</subject><subject>Histocompatibility antigen HLA</subject><subject>Immunotherapy</subject><subject>Internal Medicine</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Monoclonal antibodies</subject><subject>Patients</subject><subject>Public Health</subject><subject>Rituximab</subject><subject>Stem cell research</subject><subject>Stem cell transplantation</subject><subject>Stem Cells</subject><subject>Transplantation</subject><issn>0268-3369</issn><issn>1476-5365</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNp9kt1qFTEUhQdR7LH6AN5IQCjepOZvfnJ5KNUKBwTR65CZ7OlJmUnGJFPteQSf2oxTrRWVQBLCt9bOTlZRPKfklBLevI6CCiIxYQQTyRp8eFBsqKgrXPKqfFhsCKsazHklj4onMV4RQoUg5ePiiDPelFzQTfHtg03zVzvqFvU-IAMRXLTJHnSy3iEzB-su0cVui0cbR526PRgUE4yog2FAKWgXp0G7tPLWoSnvwKWIvti0RxpNfvG7BmS88wHHCTrb2w5ljcXZ-Mem9ebmafGo10OEZ7frcfHpzfnHswu8e__23dl2hzshm4Sl7EFSI5s8tU1Va6ioMHXLeyFNWxtGeFnSmla14ZRKaGspWyaY7IBzTiQ_Ll6tvlPwn2eISeXWlm60Az9HxQQhJWdELOjLP9ArPweXb5epuiSC5kr_p6jMTg1t7qhLPYCyrvf58bqltNpWrOG0knypePoXKg8Do-28g97m83uCk98Ee9BD2kc_zMt3xPsgXcEu-BgD9GoK-d_DjaJELXFSa5xUjpNa4qQOWfPitrO5HcH8UvzMTwbYCsRpCQqEu9b_7fodBi7Trw</recordid><startdate>20200701</startdate><enddate>20200701</enddate><creator>Chang, Ying-Jun</creator><creator>Xu, Lan-Ping</creator><creator>Wang, Yu</creator><creator>Zhang, Xiao-Hui</creator><creator>Chen, Huan</creator><creator>Chen, Yu-Hong</creator><creator>Wang, Feng-Rong</creator><creator>Han, Wei</creator><creator>Sun, Yu-Qian</creator><creator>Yan, Chen-Hua</creator><creator>Tang, Fei-Fei</creator><creator>Huo, Ming-Rui</creator><creator>Zhao, Xiang-Yu</creator><creator>Mo, Xiao-Dong</creator><creator>Liu, Kai-Yan</creator><creator>Huang, Xiao-Jun</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7QP</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-2145-6643</orcidid></search><sort><creationdate>20200701</creationdate><title>Rituximab for desensitization during HLA-mismatched stem cell transplantation in patients with a positive donor-specific anti-HLA antibody</title><author>Chang, Ying-Jun ; Xu, Lan-Ping ; Wang, Yu ; Zhang, Xiao-Hui ; Chen, Huan ; Chen, Yu-Hong ; Wang, Feng-Rong ; Han, Wei ; Sun, Yu-Qian ; Yan, Chen-Hua ; Tang, Fei-Fei ; Huo, Ming-Rui ; Zhao, Xiang-Yu ; Mo, Xiao-Dong ; Liu, Kai-Yan ; Huang, Xiao-Jun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c498t-99fe91d9891db867ae614d7b3f49db7d2035517167d3119eb799b2429ce333093</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>631/250/1854/2812</topic><topic>631/250/1904</topic><topic>Antibodies</topic><topic>Antithymocyte globulin</topic><topic>Bone marrow</topic><topic>Cell Biology</topic><topic>Desensitization</topic><topic>Hematology</topic><topic>Histocompatibility antigen HLA</topic><topic>Immunotherapy</topic><topic>Internal Medicine</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Monoclonal antibodies</topic><topic>Patients</topic><topic>Public Health</topic><topic>Rituximab</topic><topic>Stem cell research</topic><topic>Stem cell transplantation</topic><topic>Stem Cells</topic><topic>Transplantation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chang, Ying-Jun</creatorcontrib><creatorcontrib>Xu, Lan-Ping</creatorcontrib><creatorcontrib>Wang, Yu</creatorcontrib><creatorcontrib>Zhang, Xiao-Hui</creatorcontrib><creatorcontrib>Chen, Huan</creatorcontrib><creatorcontrib>Chen, Yu-Hong</creatorcontrib><creatorcontrib>Wang, Feng-Rong</creatorcontrib><creatorcontrib>Han, Wei</creatorcontrib><creatorcontrib>Sun, Yu-Qian</creatorcontrib><creatorcontrib>Yan, Chen-Hua</creatorcontrib><creatorcontrib>Tang, Fei-Fei</creatorcontrib><creatorcontrib>Huo, Ming-Rui</creatorcontrib><creatorcontrib>Zhao, Xiang-Yu</creatorcontrib><creatorcontrib>Mo, Xiao-Dong</creatorcontrib><creatorcontrib>Liu, Kai-Yan</creatorcontrib><creatorcontrib>Huang, Xiao-Jun</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Bone marrow transplantation (Basingstoke)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chang, Ying-Jun</au><au>Xu, Lan-Ping</au><au>Wang, Yu</au><au>Zhang, Xiao-Hui</au><au>Chen, Huan</au><au>Chen, Yu-Hong</au><au>Wang, Feng-Rong</au><au>Han, Wei</au><au>Sun, Yu-Qian</au><au>Yan, Chen-Hua</au><au>Tang, Fei-Fei</au><au>Huo, Ming-Rui</au><au>Zhao, Xiang-Yu</au><au>Mo, Xiao-Dong</au><au>Liu, Kai-Yan</au><au>Huang, Xiao-Jun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Rituximab for desensitization during HLA-mismatched stem cell transplantation in patients with a positive donor-specific anti-HLA antibody</atitle><jtitle>Bone marrow transplantation (Basingstoke)</jtitle><stitle>Bone Marrow Transplant</stitle><addtitle>Bone Marrow Transplant</addtitle><date>2020-07-01</date><risdate>2020</risdate><volume>55</volume><issue>7</issue><spage>1326</spage><epage>1336</epage><pages>1326-1336</pages><issn>0268-3369</issn><eissn>1476-5365</eissn><abstract>To define the efficacy of a single dose of 375 mg/m
2
rituximab for DSA-positive patients with 2000 ≤ MFI < 10,000, we enrolled a prospective clinical cohort including patients with positive DSA treated with rituximab (
n
= 55, cohort A), a matched-pair cohort including cases with negative DSA (
n
= 110, cohort B) and a historical cohort including subjects with 2000 ≤ MFI < 10,000 without receiving any treatment for DSA (
n
= 22, cohort C). The incidences of primary poor graft function (PGF) in cohort A and cohort B were 5% and 1% (
P
= 0.076), respectively, both of which were lower than that in cohort C (27%,
P
< 0.001, for all). Rituximab was associated with a reduced incidence of primary PGF (HR 0.200,
P
= 0.023). The 3-year nonrelapse mortality of patients in cohort A and cohort B were 23% and 24%, respectively, both of which were lower than that in the cohort C (37%), although no statistical significance was observed. These results led to a low 3-year overall survival in patients in the cohort C (58%) compared with those in the cohort A (71%) and the cohort B (73%). We suggest that a single dose of rituximab could be effectively used to prevent the onset of primary PGF. The prospective cohort of this study is registered at
http://www.chictr.org.cn/ChiCTR-OPC-15006672
.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>32385341</pmid><doi>10.1038/s41409-020-0928-z</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0002-2145-6643</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0268-3369 |
| ispartof | Bone marrow transplantation (Basingstoke), 2020-07, Vol.55 (7), p.1326-1336 |
| issn | 0268-3369 1476-5365 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2400532049 |
| source | Springer Nature - Complete Springer Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | 631/250/1854/2812 631/250/1904 Antibodies Antithymocyte globulin Bone marrow Cell Biology Desensitization Hematology Histocompatibility antigen HLA Immunotherapy Internal Medicine Medicine Medicine & Public Health Monoclonal antibodies Patients Public Health Rituximab Stem cell research Stem cell transplantation Stem Cells Transplantation |
| title | Rituximab for desensitization during HLA-mismatched stem cell transplantation in patients with a positive donor-specific anti-HLA antibody |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T01%3A35%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Rituximab%20for%20desensitization%20during%20HLA-mismatched%20stem%20cell%20transplantation%20in%20patients%20with%20a%20positive%20donor-specific%20anti-HLA%20antibody&rft.jtitle=Bone%20marrow%20transplantation%20(Basingstoke)&rft.au=Chang,%20Ying-Jun&rft.date=2020-07-01&rft.volume=55&rft.issue=7&rft.spage=1326&rft.epage=1336&rft.pages=1326-1336&rft.issn=0268-3369&rft.eissn=1476-5365&rft_id=info:doi/10.1038/s41409-020-0928-z&rft_dat=%3Cgale_proqu%3EA628316939%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2419204818&rft_id=info:pmid/32385341&rft_galeid=A628316939&rfr_iscdi=true |